Activity of 17β-(N-alkyl/arylformamido) and 17β-[(N-alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-50α-androstan-3-ones as 50α-reductase inhibitors in the hamster flank organ and ear

Journal of Investigative Dermatology

Volumn 111, Issue 2, 1998, Pages 273-278

  Chen, Cailin ^a   Li, Xun ^a   Singh, Shankar M ^a   Labrie, Fernand ^a  

^a LAVAL UNIVERSITY   (Canada)

Author keywords

Acne; Androgens; Costovertebral organ; Sebaceous glands

Indexed keywords

17BETA (N AMYLFORMAMIDO) 4 METHYL 4 AZA 5ALPHA ANDROSTAN 3 ONE; 17BETA (N HEPTYLFORMAMIDO) 4 METHYL 4 AZA 5ALPHA ANDROSTAN 3 ONE; 17BETA (N HEXYLFORMAMIDO) 4 METHYL 4 AZA 5ALPHA ANDROSTAN 3 ONE; ANDROSTANOLONE; ANDROSTANOLONE DERIVATIVE; EM 401; EM 402; EM 540; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; UNCLASSIFIED DRUG; ANTIANDROGEN; CHOLESTENONE 5ALPHA REDUCTASE; ENZYME INHIBITOR; OXIDOREDUCTASE;

ACNE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; HIRSUTISM; HYPERANDROGENISM; MALE; MALE TYPE ALOPECIA; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; SEBACEOUS GLAND; SEBORRHEA; SYRIAN HAMSTER; TOPICAL DRUG ADMINISTRATION; ANIMAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; EAR; HAMSTER; STRUCTURE ACTIVITY RELATION;

ANDROGEN ANTAGONISTS; ANIMALS; CHOLESTENONE 5 ALPHA-REDUCTASE; CRICETINAE; DOSE-RESPONSE RELATIONSHIP, DRUG; EAR; ENZYME INHIBITORS; MALE; MESOCRICETUS; OXIDOREDUCTASES; SEBACEOUS GLANDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031596333     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1998.00271.x     Document Type: Article

References (43)

1. Andersson S, Russel DW: Structural and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc Natl Acad Sci USA 87:3640-3644, 1990
2. Andersson S, Bergman DM, Jenkins EP, Russel DW: Deletion of steroid 5α-reductase 2 gene in male pseudophermaphroditism. Nature 354:159-161, 1991
3. Barth JH: Alopecia and hirsuties. Current concepts in pathogenesis and management. Drugs 35:83-91, 1988
4. Bouton MM, Lecaque D, Secchi J, Tournemine C: Effect of a new topically active antiandrogen (RU38882) on the rat sebaceous gland: comparison with cyproterone acetate. J Invest Dermatol 86:163-167, 1986
5. Brooks JR, Primka RL, Berman C, Krupa DA, Reynolds GF, Rasmusson GH: Topical anti-androgenicity of a new 4-azasteroid in the hamster. Steroids 56:428-433, 1991
6. Chen C, Puy LA, Simard J, Li X, Singh SM, Labrie F: Local and systemic reduction by topical finasteride or flutamide on hamster flank organ size and enzyme activity. J Invest Dermatol 105:678-682, 1995
7. Cunliffe WJ, Shuster S: Pathogenesis of acne. Lancet i:685-687, 1969a
8. Cunliffe WJ, Shuster S: The rate of sebum secretion in man. Br J Dermatol 81:697-704, 1969b
9. Cusan L, Dupont A, Bélanger A, Tremblay RR, Manhès G, Labrie F: Treatment of hirsutism with the pure antiandrogen flutamide. J Am Acad Dermatol 23:462-469, 1990
10. Cusan L, Dupont A, Cossette M, Labrie F: Flutamide in the treatment of female androgenic alopecia. Can J Dermatol 5:421-427, 1993
11. Cusan L, Dupont A, Gomez JL, Tremblay RR, Labrie F: Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial. Fertil Steril 61:281-287, 1994
12. Darley CR, Kirby JD, Besser GM, Munro DD, Edwards CR, Rees LH: Circulating testosterone, sex hormone binding globulin and prolactin in women with the late onset or persistent acne vulgaris. Br J Dermatol 106:517-522, 1982
13. Diani AR, Mulholland MJ, Shull KL, et al: Hair growth effects of oral administration of finasteride, a steroid 5α-reductase inhibitor, alone and in combination with topical minoxidil in the balding stumptail macaque. J Clin Endocrinol Metab 74:345-350, 1992
14. Grino P, Griffin J, Wilson J: Testosterone at high concentrations interacts with the human androgen receptor similarly to dihydrotestosterone. Endocrinology 126:1165-1172, 1990
15. Hamilton JB, Montagna W: The sebaceous glands of the hamster. Morphological effects of androgens on integumentary structure. Am J Anat 86:191-233, 1950
16. Harris G, Azzolina B, Baginsky W, et al: Identification and selective inhibition of an isoenzyme of steroid 5α-reductase in human scalp. Proc Natl Acad Sci USA 89:10787-10791, 1992
17. Imperato-McIngley J, Sanchez R, Spencer JR, Yee B, Vaughan ED: Comparison of the effects of the 5α-reductase inhibitor finasteride and the antiandrogen flutamide on prostate and genital differentiation: dose-response studies. Endocrinolgy 131:1149-1156, 1992
18. Kramer CY: Extension of multiple range tests to group means with unique numbers of replications. Biometrics 12:307-310, 1956
19. La Vecchia C, Franceschi S, Decarli A, Gallus G, Tognom G: Risk factors for endometrial cancer at different ages. J Natl Cancer Inst 73:667-671, 1984
20. Labrie F: Intracrinology. Mol Cell Endocrinol 78:C113-C118, 1991
21. Labrie C, Trudel C, Li S, Martel C, Couet J, Labrie F: Combination of an antiandrogen and a 5α-reductase inhibitor: A further step towards total androgen blockade? Endocrinology 129:566-568, 1991
22. Labrie F, Sugimoto Y, Luu-The V, et al: Structure of human type II 5α-reductase. Endocrinology 131:1571-1573, 1992
23. Labrie F, Cusan L, Dupont A, et al: Androgen receptor. In: Adashi EY, Rock JA, Rosenwaks Z (eds). Reproductive Endocrinology, Surgery and Technology. Lippincott-Raven Publishers, Philadelphia, 1996, pp. 560-583
24. Li X, Singh SM, Labrie F: Synthesis and in vitro activity of 17β-(N-alkyl/arolformamido)- and 17β-[(N-alkyl/aryl) alkyl/arylamido]-4-methyl-4-aza-3-oxo-5α-androstan-3-ones as inhibitors of human 5α-reductases and antagonist of the androgen receptor. J Med Chem 38:1158-1173, 1995
25. Lookingbill DP, Abrams BB, Ellis CN, et al: Inocoterone and acne. Arch Dermatol 128:1197-1200, 1992
26. Luderschmidt C, Eiermann W, Jawny J, Bidlingmaier F, Ring J: 17α-propylmesterolone (SH-434): an antiandrogenic sebosuppresive substance not influencing circulating testosterone concentrations. Experimental studies in Syrian hamsters. Nauynyn Schmiedebergs Arch Pharmacol 328:214-218, 1984
27. Lutsky BN, Budak M, Koziol P, Monahan M, Neri RO: The effects of a nonsteroid antiandrogen, Flutamide, on sebaceous gland. J Invest Dermatol 64:412-417, 1975
28. Luu-The V, Sugimoto Y, Puy L, Labrie Y, Lopez I, Singh M, Labrie F: Characterization, expression and immunohistochemical localization of 5α-reductase in human skin. J Invest Dermatol 102:221-226, 1994
29. Martel C, Trudel C, Couet J, Labrie C, Bélanger A, Labrie F: Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MA. Mol Cell Endocrinol 91:43-49, 1993
30. 4 isomerase (3β-HSD), 17β-HSD 5α-reductase and aromatase activities in the rhesus monkey. Mol Cell Endocrinol 104:103-111, 1994
31. Matias JR, Gaillard M: Local inhibition of sebaceous gland growth by topically applied (RU 58841). Ann N Y Acad Sci 761:56-65, 1995
32. Neumann F, Steinback H: Androgens and antiandrogens. In: Eichler O, Farh A, Herken H, Weleh AD (eds). Berlin Heidelberg, Springer-Verlag, New York, 1991, p. 236
33. Plewig G, Luderschmidt C: Hamster car model for sebaceous glands. J Invest Dermatol 68:171-176, 1982
34. Plewig G, Luderschmidt C: Effect of antiandrogen on sebaceous glands and acne vulgaris. Animal experiments and studies in acne patients. In: Hammerstein J, Lachnia-Fixon U (eds). Androgenization in Women. Excerpta Medica, Amsterdam, Oxford, 1991, pp. 96-102
35. Pochi PE, Straus JS: Sebum production, casual sebum levels, titrable acidity of sebum, and urinary fractional, 17-ketosteroid excretion in males with acne. J Invest Dermatol 43:383-388, 1964
36. Rittmaster RS: Topical antiandrogens in the treatment of male pattern baldness. Clin Dermatol 6:122-128, 1988
37. Rittmaster RS, Vno, H, Povar ML, Mellin T, Loriaux D: The effects of N,N-diethyl-4-methyl-3-oxo-4-aza-5α-androstane-17β-carboxamide, a 5α-reductase inhibitor and antiandrogen, on the development of baldness in the stumptail macaque. J Clin Endocrinol Metab 65:188-193, 1987
38. Stoner E: The clinical development of a 5α-reductase inhibitor, finasteride. J Steroid Biochem Mol Biol 37:375-378, 1990
39. Vermorken AJM, Goos CMAA, Roelofs HMJ: The antiandrogenic effect of progesterone on the hamster flank organ. Br J Dermatol 102:455-460, 1980
40. Vermorken AJM, Goos CMAA, Wirtz P: Evaluation of the hamster flank organ test for the screening of antiandrogens. Br J Dermatol 106:99-101, 1982
41. Voigt W, Hsia SI: The antiandrogen action of 4-androsten-3-one 17a-carboxyl acid and its methyl ester in hamster flank organ. Endocrinology 92:1216-1222, 1973
42. Weissmann A, Bowden J, Frank BL, Horwitz SN, Frost P: Antiandrogenic effects of topically applied spironolactone on the hamster flank organ. Arch Dermatol 121:57-62, 1985
43. Zarate A, Mahesh VB, Greenblatt RB: Effect of an antiandrogen 17α-methyl-B-nortestosterone, on acne and hirsutism. J Clin Endocrinol Metab 26:1394-4398, 1966